千金藥業(600479.SH):仿製藥品纈沙坦膠囊擬中標全國藥品集採
格隆匯 8 月 20日丨千金藥業(600479.SH)公佈,按照國家組織藥品集中採購和使用聯合採購辦公室關於發佈《全國藥品集中採購文件(GY-YD2020-1)》的公告要求,2020年8月20日,公司控股子公司湖南千金湘江藥業股份有限公司(“千金湘江藥業”)參加了國家藥品集中採購投標工作,千金湘江藥業已通過國家藥品監督管理局仿製藥質量和療效一致性評價的仿製藥品纈沙坦膠囊擬中標本次集中採購。
此次國家組織藥品集中採購和使用工作由全國各省份和新疆生產建設兵團組成採購聯盟,聯盟地區所有公立醫療機構和軍隊醫療機構全部參加,醫保定點社會辦醫療機構、醫保定點零售藥店自願參加。
千金湘江藥業本次擬中標的產品纈沙坦膠囊於2020年4月7日獲得國家藥品監督管理局核准簽發的《藥品補充申請批件》。該產品2019年銷售收入為17458.96萬元,佔公司2019年營業收入的4.95%;2020年一季度銷售收入為3587.94萬元,佔公司2020年一季度營業收入的4.17%。
公司響應“帶量採購”相關政策,通過技術創新有效降低生產成本並讓利於患者,擬中標國家藥品集中採購。本次公司擬中選價格與原中標價格相比有一定程度下降。後續簽訂採購合同並實施後,將有利於促進公司相關產品的銷售,提高市場佔有率,提升品牌影響力,對公司的未來經營業績產生積極的影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.